文献速递支持与姑息治疗

欧洲癌症患者中SARS-CoV-2疫情的临床特征分析

Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients.
PubMed 文献 · Cancer Discov · 2020-07-31

该多中心研究纳入890例确诊Covid-19的癌症患者,发现从乳腺癌到血液系统恶性肿瘤死亡率呈恶化梯度,男性、高龄和合并症数量多可识别死亡率显著更差的患者亚组,化疗、靶向治疗和免疫治疗未增加死亡率,抗疟药暴露与死亡率改善相关。

要点

  • 癌症类型影响Covid-19死亡率,从乳腺癌到血液系统恶性肿瘤呈恶化梯度
  • 男性、高龄和合并症数量多与Covid-19死亡率显著更差相关
  • 化疗、靶向治疗和免疫治疗未 worsen 死亡率,抗疟药暴露与死亡率改善相关

核心结论

  • 癌症患者Covid-19死亡率随恶性肿瘤类型从乳腺癌到血液系统肿瘤呈恶化梯度。
  • 男性、高龄和合并症数量多可识别Covid-19死亡率显著更差的患者亚组。
  • 化疗、靶向治疗和免疫治疗未恶化死亡率,抗疟药暴露与死亡率改善独立相关。

研究设计与样本

  • 多中心研究纳入890例确诊Covid-19的癌症患者。

主要发现

  • 从乳腺癌到血液系统恶性肿瘤观察到死亡率恶化梯度。
  • 男性、高龄和合并症数量多与Covid-19死亡率显著更差相关。
  • 化疗、靶向治疗和免疫治疗未恶化死亡率。
  • 抗疟药暴露与死亡率改善相关,独立于基线预后因素。

临床怎么用

  • 可利用人口学因素对癌症患者Covid-19风险进行个体化分层。
  • 化疗、靶向治疗和免疫治疗未显示恶化死亡率,但需个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The SARS-Cov-2 pandemic significantly impacted on oncology practice across the globe. There is uncertainty as to the contribution of patients' demographics and oncological features on severity and mortality from Covid-19 and little guidance as to the role of anti-cancer and anti-Covid-19 therapy in this population. In a multi-center study of 890 cancer patients with confirmed Covid-19 we demonstrated a worsening gradient of mortality from breast cancer to haematological malignancies and showed that male gender, older age, and number of co-morbidities identifies a subset of patients with significantly worse mortality rates from Covid-19. Provision of chemotherapy, targeted therapy and immunotherapy did not worsen mortality. Exposure to antimalarials was associated with improved mortality rates independent of baseline prognostic factors. This study highlights the clinical utility of demographic factors for individualized risk-stratification of patients and support further research into emerging anti-Covid-19 therapeutics in SARS-Cov-2 infected cancer patients.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Pinato DJ, Zambelli A, Aguilar-Company J, et al. Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. Cancer Discov. 2020. PMID: 32737082. doi:10.1158/2159-8290.CD-20-0773

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。